Cochrane · systematic review · CD012494
Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings
Yu, A, Wu, S, Zhang, Z, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Dementia and Cognitive ImprovementAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
3
No studies
4
Included studies
NR
No studies 4 · 57.1%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Cholinesterase inhibitors (rivastigmine) compared to placebo for the treatment of delirium in non‐ICU settings
Population: people with delirium
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Duration of delirium days Cholinesterase inhibitors (rivastigmine) vs placebo | no estimate extracted | 1 study · 15 participants | Low Downgraded: imprecision |
Severity of delirium CAM negative Cholinesterase inhibitors (rivastigmine) vs placebo | no estimate extracted | NR | No studies |
Adverse events nausea Cholinesterase inhibitors (rivastigmine) vs placebo | RR 0.3 [0.01, 6.29] | 1 study · 15 participants | Low Downgraded: imprecision |
Persistent cognitive impairment Cholinesterase inhibitors (rivastigmine) vs placebo | no estimate extracted | NR | No studies |
Length of hospitalisation Cholinesterase inhibitors (rivastigmine) vs placebo | no estimate extracted | NR | No studies |
Mortality Cholinesterase inhibitors (rivastigmine) vs placebo | RR 0.1 [0.01, 1.56] | 1 study · 15 participants | Low Downgraded: imprecision |
Cost of intervention Cholinesterase inhibitors (rivastigmine) vs placebo | no estimate extracted | NR | No studies |